A combination of faecal tests for the detection of colon cancer: A new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 10, 2012, Pages 1145-1152

  Parente, Fabrizio ^a   Marino, Barbara ^a   Ilardo, Antonina ^b   Fracasso, Pierluigi ^e   Zullo, Angelo ^f   Hassan, Casare ^f   Moretti, Roberto ^c   Cremaschini, Marco ^c   Ardizzoia, Antonio ^a   Saracino, Ilaria ^d   Perna, Federico ^d   Vaira, Dino ^d  

^a A MANZONI HOSPITAL   (Italy)

^b Colorectal Cancer Screening Unit Community Health Care Centre ^*  (Italy)

^c Local Health Care Centre   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e ASL Roma B   (Italy)

^f Regina Margherita Hospital   (Italy)

Author keywords

advanced adenoma; colon cancer screening; colorectal cancer; faecal; faecal calprotectin; immunochemical faecal occult blood test; pyruvate kinase (M2 PK)

Indexed keywords

CALGRANULIN; PYRUVATE KINASE; PYRUVATE KINASE M2 PK; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; COLON CANCER; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOMA; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; COLONOSCOPY; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRUVATE KINASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84866322447     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328355cc79     Document Type: Article

References (32)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-592. (Pubitemid 46359643)
2. Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmeigam BR. Prevalence of adenomas and colorectal cancer in average risk individuals. A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 12:1272-1278.
3. Winawer SJ. Natural history of colorectal cancer. Am J Med 1999; 106:3s-6s. (Pubitemid 29100862)
4. Brenner H, Altenhofen N, Hoffmeister M. Eight years of bowel cancer screening in Germany: initial findings and projections. Dtsch Arztebl Int 2010; 107:753-759.
5. Towler B, Irwig L, Glaszious P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test. BMJ 1998; 31:559-565. (Pubitemid 28395924)
6. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; 1:CD001216.
7. Ahlquist D, Wieland H, Moertel C, McGill DB, Loprinzi CL, O'Connel MJ, et al. Accuracy of fecal occult blood test screening for colorectal neoplasia:a prospective study using Hemoccult and Hemo Quant tests. JAMA 1993; 269:1262-1267. (Pubitemid 23067429)
8. Allison J, Tekawa I, Ransom L. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155-159. (Pubitemid 26017953)
9. Lieberman DA, Weiss DG. Veteran Affairs Cooperative study group. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-560. (Pubitemid 32772096)
10. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in asymptomatic population. Gastroenterology 2005; 129:422-428. (Pubitemid 41096630)
11. Roseth AG, Fagerhol MK, Aadland E, Schionsby H. Assessment of the neutrophil dominant protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27:793-798.
12. Tibble J, Sightorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49:402-408. (Pubitemid 32802576)
13. Meucci G, D'Incà R, Maieron R, Orzes N, Vecchi M, Visentini D, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicentre prospective study. Dig Liver Dis 2010; 42: 191-195.
14. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341:c3369.
15. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2 pyruvate-kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007; 19: 265-276.
16. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, Moslein G. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005; 130:872-877. (Pubitemid 40545296)
17. Shastri Y, Naumann M, Oremek G, Hanish E, Rosch W, Mossner J, et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type (M2-PK) as screening biomarker for colorectal neoplasia. Int J Cancer 2006; 119:2651-2656. (Pubitemid 44691321)
18. Haug U, Rothenbacher D, Wente M, Seiler C, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults versus colorectal cancer patients. Br J Cancer 2007; 96:1329-1334. (Pubitemid 46685781)
19. Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rosch W, et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol 2008; 103:1496-1504. (Pubitemid 351813913)
20. Parente F, Marino M, De Vecchi N, Moretti R. Lecco Cancer Screening Group. Faecal occult blood test-based screening programme with high compliance for colonoscopy has strong clinical impact on colorectal cancer. Brit J Surg 2009; 96:533-540.
21. Grande E, Inghelmann R, Francisci S, Verdecchia A, Micheli A, Baili P, et al. Regional estimates of colorectal cancer burden in Italy. Tumori 2007; 93:352-359. (Pubitemid 47403450)
22. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8:784-796. (Pubitemid 47321601)
23. West NJ, Boustiere C, Fischbach W, Parente F, Leicester RJ. Colorectal cancer screening in Europe: differences in approach; similar barrier to overcome. Int J Colorectal Dis 2009; 96:731-740.
24. Zorzi M, Fedato C, Naldoni C, Sassatelli R, Sassoli De, Bianchi P, Senore C, et al. Screening for colorectal cancer in Italy: 2007 survey. Epidemiol Prev 2009; 33 (Suppl 2):57-74.
25. Parente F, Marino B, Ardizzoia A, Ucci G, Ilardo A, Limonta F, et al. Impact of a Population-Based Colorectal Cancer Screening Program on Local Health Services Demand in Italy: a 7-year survey in a Northern Province. Am J Gastroenterol 2011; 106:1986-1993.
26. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumour M2-PK. World J Gastroenterol 2006; 12:7007-7011. (Pubitemid 44834892)
27. Hardt P, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new sensitive screening tool for colorectal cancer. Br J Cancer 2004;980-984. (Pubitemid 39273794)
28. Jeffery J, Lewis S, Ayling RM. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disease. Inflamm Bowel Dis 2009; 15:1630-1634.
29. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis 2008; 10:244-248. (Pubitemid 351284676)
30. Mulder SA, van Leerdam ME, van Vuren AJ, Francke J, van Toorenebergen AW, Kuipers EJ, Ouwendijk RJ. Tumor pyruvate kinase isoenzime type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepato 2007; 19: 878-882. (Pubitemid 47415147)
31. Steele RJ, Gnauck R, Hrcka R, Kronborg O, Kuntz C, Moayyedi P, et al. Methods and economic considerations: Group 1 Report. ESGE/UEGF Colorectal Cancer-Public Awareness Campaign. Endoscopy 2004; 36: 349-353. (Pubitemid 38444448)
32. Haug U, Brenner H. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy. Cancer Epidemiol Biomarkers Prev 2005; 14:422-428. (Pubitemid 40270107)